A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept

Trial Profile

A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms TITAN
  • Sponsors Bayer
  • Most Recent Events

    • 21 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 12 May 2017 Planned End Date changed from 21 Apr 2017 to 6 Jun 2017.
    • 17 Apr 2017 Planned End Date changed from 1 Feb 2017 to 21 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top